Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges

References

• Ecotiere L, Thierry A, Debiais-Delpech C, et al. Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transplant. 2016;31(1):64–72. doi:10.1093/ndt/gfv283
   PubMed Web of Science ®Google Scholar
• Zand L, Nasr SH, Gertz MA, et al. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leuk Lymphoma. 2015;56(12):3357–3364. doi:10.3109/10428194.2015.1040011
   PubMed Web of Science ®Google Scholar
• Sathick IJ, Drosou ME, Leung N. Myeloma light chain cast nephropathy, a review. J Nephrol. 2019;32(2):189–198. doi:10.1007/s40620-018-0492-4
   PubMed Web of Science ®Google Scholar
• Royal V, Leung N, Troyanov S, et al. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood. 2020;135(21):1833–1846. doi:10.1182/blood.2019003807
   PubMed Web of Science ®Google Scholar
• Kumar S, Muchmore A. Tamm-Horsfall protein–uromodulin (1950–1990). Kidney Int. 1990;37(6):1395–1401. doi:10.1038/ki.1990.128
   PubMed Web of Science ®Google Scholar
• Huang ZQ, Kirk KA, Connelly KG, Sanders PW. Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J Clin Invest. 1993;92(6):2975–2983. doi:10.1172/JCI116920
   PubMed Web of Science ®Google Scholar
• Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol. 2001;158(5):1859–1866. doi:10.1016/s0002-9440(10)64142-9
   PubMed Web of Science ®Google Scholar
• Serafini-Cessi F, Malagolini N, Cavallone D. Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis. 2003;42(4):658–676. doi:10.1016/S0272-6386(03)00829-1
   PubMed Web of Science ®Google Scholar
• Thajudeen B, Rubin MF. Hemodynamic acute kidney injury in immunoglobulin A nephropathy: nephrosarca theory revisited. Am J Med. 2013;126(12):e13–4. doi:10.1016/j.amjmed.2013.07.033.
   PubMed Web of Science ®Google Scholar
• Oyama Y, Iwafuchi Y, Morioka T, Narita I. Acute kidney injury associated with minimal change nephrotic syndrome in an elderly patient successfully treated with both fluid management and specific therapy based on kidney biopsy findings. Case Rep Nephrol Dial. 2020;10(1):42–50. doi:10.1159/000507426
   PubMed Web of Science ®Google Scholar
• Batuman V, Verroust PJ, Navar GL, et al. Myeloma light chains are ligands for cubilin (gp280). Am J Physiol. 1998;275(2 Pt 2):F246–254. doi:10.1152/ajprenal.1998.275.2.F246
   PubMed Web of Science ®Google Scholar
• Klassen RB, Allen PL, Batuman V, Crenshaw K, Hammond TG. Light chains are a ligand for megalin. J Appl Physiol. 2005;98(1):257–263. doi:10.1152/japplphysiol.01090.2003
   PubMed Web of Science ®Google Scholar
• Sanders PW. Mechanisms of light chain injury along the tubular nephron. J Am Soc Nephrol. 2012;23(11):1777–1781. doi:10.1681/asn.2012040388
   PubMed Web of Science ®Google Scholar
• Loutradis C, Price A, Ferro CJ, Sarafidis P. Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction. J Hum Hypertens. 2021;35(6):499–509. doi:10.1038/s41371-021-00504-9.
   PubMed Web of Science ®Google Scholar
• Takata T, Isomoto H. Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: renoprotective mechanisms beyond glycemic control. Int J Mol Sci. 2021;22(9):4374. doi:10.3390/ijms22094374
   PubMed Web of Science ®Google Scholar
• Menè P, De Alexandris L, Moioli A, Raffa S, Stoppacciaro A. Monoclonal gammopathies of renal significance: renal biopsy and beyond. Cancers. 2020;12(7):1741. doi:10.3390/cancers12071741
   PubMed Web of Science ®Google Scholar
• Menè P, Moioli A, Stoppacciaro A, Lai S, Festuccia F. Acute kidney injury in monoclonal gammopathies. J Clin Med. 2021;10(17):3871. doi:10.3390/jcm10173871
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Sonneveld P, Leung N, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544–1557. doi:10.1200/JCO.2015.65.0044
   PubMed Web of Science ®Google Scholar
• Knudsen LM, Hjorth M, Hippe E; Nordic Myeloma Study Group. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Haematol. 2000;65(3):175–181. doi:10.1034/j.1600-0609.2000.90221.x
   PubMed Web of Science ®Google Scholar
• Herrera GA, Picken MM. Renal diseases associated with plasma cell dyscrasias, amyloidoses, and Waldenström macroglobulinemia. Jennette JC, Olson JL, Silva FG, D’Agati VD, editors. Heptinstall’s Pathology of the Kidney. 7th ed. Chapter 22. Philadelphia: Wolters Kluwer; 2014: 951–1014
   Google Scholar
• Horton JK, Davies M, Topley N, Thomas D, Williams JD. Activation of the inflammatory response of neutrophils by Tamm–Horsfall glycoprotein. Kidney Int. 1990;37(2):717–726. doi:10.1038/ki.1990.38
   PubMed Web of Science ®Google Scholar
• Sengul S, Zwizinski C, Simon EE, Kapasi A, Singhal PC, Batuman V. Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int. 2002;62(6):1977–1988. doi:10.1046/j.1523-1755.2002.00660.x
   PubMed Web of Science ®Google Scholar
• Basnayake K, Ying WZ, Wang PX, Sanders PW. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc Nephrol. 2010;21(7):1165–1173. doi:10.1681/asn.2009101089
   PubMed Web of Science ®Google Scholar
• Ying WZ, Wang PX, Aaron KJ, Basnayake K, Sanders PW. Immunoglobulin light chains activate nuclear factor κB in renal epithelial cells through a Src-dependent mechanism. Blood. 2011;117(4):1301–1307. doi:10.1182/blood-2010-08-302505
   PubMed Web of Science ®Google Scholar
• Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med. 1991;324(26):1845–1851. doi:10.1056/nejm199106273242603
   PubMed Web of Science ®Google Scholar
• Sanders PW, Booker BB, Bishop JB, Cheung HC. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest. 1990;85(2):570–576. doi:10.1172/JCI114474
   PubMed Web of Science ®Google Scholar
• Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. Br Med J. 2020;370:m2687. doi:10.1136/bmj.m2687
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33):4976–4984. doi:10.1200/jco.2010.30.8791
   PubMed Web of Science ®Google Scholar
• Munier A, Gras V, Andrejak M, et al. Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother. 2005;39(7–8):1194–1197. doi:10.1345/aph.1E589
   PubMed Web of Science ®Google Scholar
• Weide R, Koppler H, Antras L, et al. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs.ibandronate: a retrospective medical records review. J Cancer Res Ther. 2010;6(1):31–35. doi:10.4103/0973-1482.63570
   PubMed Web of Science ®Google Scholar
• Cicci JD, Buie L, Bates J, van Deventer H. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leuk. 2014;14(6):e207–211. doi:10.1016/j.clml.2014.07.005
   PubMedGoogle Scholar
• Dietzek A, Connelly K, Cotugno M, Bartel S, McDonnell AM. Denosumab in hypercalcemia of malignancy: a case series. J Oncol Pharm Pract. 2015;21(2):143–147. doi:10.1177/1078155213518361
   PubMed Web of Science ®Google Scholar
• Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12(6):1164–1172. doi:10.1681/ASN.V1261164
   PubMed Web of Science ®Google Scholar
• Magni A, Agostoni P, Bonezzi C, et al. Management of osteoarthritis: expert opinion on NSAIDs. Pain Ther. 2021;10(2):783–808. doi:10.1007/s40122-021-00260-1
   PubMed Web of Science ®Google Scholar
• McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology. 1992;183(2):519–521. doi:10.1148/radiology.183.2.1561361
   PubMed Web of Science ®Google Scholar
• Kooiman J, Pasha SM, Zondag W, et al. Meta-analysis: serum creatinine changes following contrast enhanced CT imaging. Eur J Radiol. 2012;81(10):2554–2561. doi:10.1016/j.ejrad.2011.11.020
   PubMed Web of Science ®Google Scholar
• Moos SI, van Vemde DN, Stoker J, Bipat S. Contrast-induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis. Eur J Radiol. 2013;82(9):e387–399. doi:10.1016/j.ejrad.2013.04.029
   PubMed Web of Science ®Google Scholar
• Stacul F, Bertolotto M, Thomsen HS, et al. Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2018;28(2):683–691. doi:10.1007/s00330-017-5023-5
   PubMed Web of Science ®Google Scholar
• Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med. 2004;128(8):875–879. doi:10.5858/2004-128-875-RPSIAA
   PubMed Web of Science ®Google Scholar
• van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–427. doi:10.1016/S0140-6736(21)00135-5
   PubMed Web of Science ®Google Scholar
• Fish R, Pinney J, Jain P, et al. The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol. 2010;5(11):1977–1980. doi:10.2215/CJN.00650110
   PubMed Web of Science ®Google Scholar
• Nasr SH, Valeri AM, Sethi S, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012;59(6):786–794. doi:10.1053/j.ajkd.2011.12.028
   PubMed Web of Science ®Google Scholar
• Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231–239. doi:10.2215/CJN.08640811
   PubMed Web of Science ®Google Scholar
• Akilesh S, Alem A, Nicosia RF. Combined crystalline podocytopathy and tubulopathy associated with multiple myeloma. Hum Pathol. 2014;45(4):875–879. doi:10.1016/j.humpath.2013.10.007
   PubMed Web of Science ®Google Scholar
• Lin ZS, Qin AB, Wang SX, et al. A non-invasive differential diagnostic model for light chain cast nephropathy in newly diagnosed multiple myeloma patients with renal involvement: a multicenter study. J Nephrol. 2021;34(4):1169–1177. doi:10.1007/s40620-020-00926-7
   PubMed Web of Science ®Google Scholar
• Khan R, Apewokin S, Grazziutti M, et al. Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. Leukemia. 2015;29(5):1195–1201. doi:10.1038/leu.2015.15
   PubMed Web of Science ®Google Scholar
• Bridoux F, Leung N, Belmouaz M, et al. Management of acute kidney injury in symptomatic multiple myeloma. Kidney Int. 2021;99(3):570–580. doi:10.1016/j.kint.2020.11.010
   PubMed Web of Science ®Google Scholar
• Sanders PW. Pathogenesis and treatment of myeloma kidney. J Lab Clin Med. 1994;124(4):484–488.
   PubMed Web of Science ®Google Scholar
• Heher EC, Goes NB, Spitzer TR, et al. Kidney disease associated with plasma cell dyscrasias. Blood. 2010;116(9):1397–1404. doi:10.1182/blood-2010-03-258608
   PubMed Web of Science ®Google Scholar
• Nicholas Burwick N, Sharma S. Glucocorticoids in multiple myeloma: past, present, and future. Ann Hematol. 2019;98(1):19–28. doi:10.1007/s00277-018-3465-8
   PubMed Web of Science ®Google Scholar
• Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130:1565–1575. doi:10.1172/JCI129205
   PubMed Web of Science ®Google Scholar
• Kleber M, Ihorst G, Deschler B, et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol. 2009;83(6):519–527. doi:10.1111/j.1600-0609.2009.01318.x
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Kyle R, Fermand JP, et al.; International Myeloma Workshop Consensus Panel 3. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus. Blood. 2011;117(18):4701–4705. doi:10.1182/blood-2010-10-299529
   PubMed Web of Science ®Google Scholar
• Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant. 2010;25(2):419–426. doi:10.1093/ndt/gfp488
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma. 2009;9(4):302–306. doi:10.3816/CLM.2009n.059
   PubMedGoogle Scholar
• Hutchison CA, Cockwell P, Stringer S. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22(6):1129–1136. doi:10.1681/ASN.2010080857
   PubMed Web of Science ®Google Scholar
• Herrera GA. The kidney in plasma cell dyscrasias: a current view and a look at the future. Contrib Nephrol. 2007;153:1–4. doi:10.1159/000096756
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Batuman V, Behrens J, et al.; International Kidney and Monoclonal Gammopathy Research Group. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol. 2011;8(1):43–51. doi:10.1038/nrneph.2011.168.
   PubMed Web of Science ®Google Scholar
• Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008;73(11):12882–12888. doi:10.1038/ki.2008.108
   Web of Science ®Google Scholar
• Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1684–1690. doi:10.2215/CJN.02290508
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Bladé J, Cockwell P, et al.; International Kidney and Monoclonal Gammopathy Research Group. Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol. 2012;8(4):234–243. doi:10.1038/nrneph.2012.14.
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007;18:886–895. doi:10.1681/ASN.2006080821
   PubMed Web of Science ®Google Scholar
• Walther C, Podoll AS, Finkel KW. Treatment of acute kidney injury with cast nephropathy. Clin Nephrol. 2014;82(1):1–6. doi:10.5414/CN108293
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009;4(4):745–754. doi:10.2215/CJN.04590908
   PubMed Web of Science ®Google Scholar
• Korsak J, Wańkowicz Z. New options of apheresis in renal diseases: how and when? Blood Purif. 2016;41(1–3):1–10. doi:10.1159/000439238
   PubMed Web of Science ®Google Scholar
• Sumak KH, Rock GA. Therapeutic plasma exchange. N Engl J Med. 1984;22(12):762–771. doi:10.1056/NEJM198403223101206
   Web of Science ®Google Scholar
• Clark WF, Stewart KA, Rock GA, et al.; Canadian Apheresis Group. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;143(11):777–784. doi:10.7326/0003-4819-143-11-200512060-00005.
   PubMed Web of Science ®Google Scholar
• Rousseau-Gagnon M, Agharazii M, De Serres A, Desmeules S. Effectiveness of haemodiafiltration with heat-sterilized High-Flux Polyphenylene HF dialyzer in reducing free light chains in patients with myeloma cast nephropathy. PLoS One. 2015;10(10):e0140463. doi:10.1371/journal.pone.0140463
   PubMed Web of Science ®Google Scholar
• Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol. 2005;16(8):2421–2430. doi:10.1681/ASN.2005010070
   PubMed Web of Science ®Google Scholar
• Gondouin B, Hutchison CA. High cut-off dialysis membranes: current uses and future potential. Adv Chronic Kidney Dis. 2011;18(3):180–187. doi:10.1053/j.ackd.2011.02.006
   PubMed Web of Science ®Google Scholar
• Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47(4):673–680. doi:10.1093/clinchem/47.4.673
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Harding S, Mead G, et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs. 2008;32:910–917. doi:10.1111/j.1525-1594.2008.00653.x
   PubMed Web of Science ®Google Scholar
• Bridoux F, Carron P-L, Pegourie B, et al. Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis Independence among patients with myeloma cast nephropathy. JAMA. 2017;318(21):2099–2110. doi:10.1001/jama.2017.17924
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Cockwell P, Moroz V, et al. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a Phase 2 randomised controlled trial. Lancet Haematol. 2019;6(4):e217–e228. doi:10.1016/S2352-3026(19)30014-6
   PubMed Web of Science ®Google Scholar
• Fabbrini P, Finkel K, Gallieni M, et al. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology. J Nephrol. 2016;29(6):735–746. doi:10.1007/s40620-016-0347-9
   PubMed Web of Science ®Google Scholar
• Wolley M, Jardine M, Hutchison CA. Exploring the clinical relevance of providing increased removal of large middle molecules. Clin J Am Soc Nephrol. 2018;13(5):805–814. doi:10.2215/CJN.10110917
   PubMed Web of Science ®Google Scholar
• Krishnasamy R, Hawley CM, Jardine MJ, et al. Design and methods of the REMOVAL-HD study: a tRial evaluating mid cut-off value membrane clearance of albumin and light chains in haemo dialysis patients. BMC Nephrol. 2018;19(1):89. doi:10.1186/s12882-018-0883-8
   PubMed Web of Science ®Google Scholar
• Grooteman MPC, van den Dorpel MA, Bots ML, et al.; CONTRAST Investigators. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol. 2012;23(6):1087–1096. doi:10.1681/ASN.2011121140.
   PubMed Web of Science ®Google Scholar
• Bolasco P, Ghezzi PM, Serra A, et al. Effects of acetate-free haemodiafiltration (HDF) with endogenous reinfusion (HFR) on cardiac troponin levels. Nephrol Dial Transplant. 2011;26(1):258–263. doi:10.1093/ndt/gfq359
   PubMed Web of Science ®Google Scholar
• Fiorenzi A. Online hemodiafiltration systems by Bellco: flexya. In: Nubé MJ, Grooteman MPC, Blankestijn P, editors. Hemodiafiltration Theory, Technology and Clinical Practice. Switzerland: Springer Nature; 2016:87–94. doi:10.1007/978-3-319-23332-1_7
   Google Scholar
• Valleè AG, Chenine L, Leray-Moragues H, et al. Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study. Nephrol Dial Transplant. 2011;26(11):3627–3633. doi:10.1093/ndt/gfr180
   PubMed Web of Science ®Google Scholar
• Pasquali S, Iannuzzella F, Corradini M, et al. A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR). J Nephrol. 2015;28(2):251–254. doi:10.1007/s40620-014-0130-8
   PubMed Web of Science ®Google Scholar
• Bourguignon C, Chenine L, Bargnoux AS, et al. Hemodiafiltration improves free light chain removal and normalizes κ/λ ratio in hemodialysis patients. J Nephrol. 2016;29(2):251–257. doi:10.1007/s40620-015-0207-z
   PubMed Web of Science ®Google Scholar
• Wratten ML, Ghezzi PM. Hemodiafiltration with endogenous reinfusion. Contrib Nephrol. 2007;158:94–102. doi:10.1159/000107239
   PubMed Web of Science ®Google Scholar
• Menè P, Giammarioli E, Fofi C, et al. Serum-free light chains removal by HFR hemodiafiltration in patients with multiple myeloma and acute kidney injury: a case series. Kidney Blood Press Res. 2018;43(4):1263–1272. doi:10.1159/000492408
   PubMed Web of Science ®Google Scholar
• Szabo AG, Thorsen J, Iversen KF, et al. Clinically-suspected cast nephropathy: a retrospective, national, real-world study. Am J Hematol. 2020;95(11):1352–1360. doi:10.1002/ajh.25959
   PubMed Web of Science ®Google Scholar